Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Want to see ACRV full AI Analyst Report?
Top Page
Acrivon Therapeutics, Inc.
(NASDAQ:ACRV)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▲(12.36% Upside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by weak financial performance (no revenue, sizable ongoing losses, and sustained cash burn). Offsetting this are constructive recent corporate updates around ACR-368 clinical progress and a stated cash runway into Q2 2027, while technicals are mixed-to-neutral and valuation signals are limited by a negative P/E and no dividend.
Positive Factors
Proprietary AP3 platform & CLIA lab
Owning the AP3 biomarker platform and a CLIA-certified lab creates durable competitive advantages: it enables prospective patient selection, accelerates trial enrollment, supports companion diagnostic development, and strengthens partner/BD opportunities that persist beyond short-term data readouts.
Negative Factors
Pre-revenue with sustained losses
The company remains pre-revenue and loss-making, meaning long-term value hinges entirely on clinical and regulatory success. Persistent operating losses create a binary outcome profile: therapeutic approval is required to generate recurring revenue, keeping structural risk elevated for months to years.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary AP3 platform & CLIA lab
Owning the AP3 biomarker platform and a CLIA-certified lab creates durable competitive advantages: it enables prospective patient selection, accelerates trial enrollment, supports companion diagnostic development, and strengthens partner/BD opportunities that persist beyond short-term data readouts.
Read all positive factors
Acrivon Therapeutics, Inc. (ACRV) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$75.76M
Dividend YieldN/A
Average Volume (3M)996.44K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue GrowthN/A
EPS Growth9.80%
CountryUS
Employees75
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,801,727
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.27
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit89.56
Enterprise Value/Ebitda-0.24
Forecast
1Y Price Target
$11.20Price Target Upside529.21% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.31M
Acrivon Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient respon...
How the Company Makes Money
As a clinical-stage biotechnology company, Acrivon Therapeutics’ ability to generate recurring product revenue is not publicly evidenced; it typically would not have meaningful commercial sales until a drug is approved. null...
Acrivon Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 228.00K | -1.36M | -1.01M | -536.00K | 0.00 | 0.00 |
| EBITDA | -85.67M | -82.76M | -79.55M | -59.85M | -32.29M | -16.15M |
| Net Income | -77.27M | -77.91M | -80.56M | -60.39M | -31.17M | -16.24M |
Balance Sheet | ||||||
| Total Assets | 107.83M | 129.72M | 196.59M | 138.26M | 181.23M | 106.59M |
| Cash, Cash Equivalents and Short-Term Investments | 97.74M | 118.58M | 179.48M | 127.46M | 127.75M | 99.60M |
| Total Debt | 2.42M | 2.71M | 3.65M | 4.64M | 4.96M | 5.63M |
| Total Liabilities | 12.32M | 17.20M | 19.80M | 17.07M | 10.75M | 130.40M |
| Stockholders Equity | 95.52M | 112.52M | 176.79M | 121.19M | 170.47M | -23.81M |
Cash Flow | ||||||
| Free Cash Flow | -66.29M | -65.33M | -68.44M | -43.93M | -32.28M | -14.22M |
| Operating Cash Flow | -64.67M | -63.66M | -65.67M | -42.64M | -30.12M | -13.98M |
| Investing Cash Flow | 60.01M | 66.10M | -51.77M | 50.72M | -141.68M | -238.00K |
| Financing Cash Flow | -439.00K | -749.00K | 121.03M | -1.55M | 101.71M | 112.22M |
Acrivon Therapeutics, Inc. Technical Analysis
Negative
1.78
Price Trends
1.72
Positive
1.81
Negative
1.83
Negative
Market Momentum
0.05
Positive
44.79
Neutral
11.22
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ACRV, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 1.93, above the 50-day MA of 1.72, and below the 200-day MA of 1.83, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 44.79 is Neutral, neither overbought nor oversold. The STOCH value of 11.22 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ACRV.
Acrivon Therapeutics, Inc. Risk Analysis
Acrivon Therapeutics, Inc. disclosed 82 risk factors in its most recent earnings report. Acrivon Therapeutics, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Acrivon Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
ACRV
Acrivon Therapeutics, Inc.
1.65
0.47
39.83%
MNOV
Medicinova
1.39
-0.01
-0.71%
ALGS
Aligos Therapeutics
5.36
-0.53
-9.00%
GNTA
Genenta Science SpA Sponsored ADR
0.63
-3.67
-85.33%
IMMX
Immix Biopharma
8.99
6.88
326.07%
CAMP
CAMP4 Therapeutics Corporation
4.56
2.37
108.22%
Acrivon Therapeutics, Inc. Corporate Events
Business Operations and StrategyFinancial Disclosures
Acrivon Highlights Positive ACR-368 Data and 2025 Results
Positive
Mar 19, 2026
On March 19, 2026, Acrivon Therapeutics reported fourth quarter and full-year 2025 results, highlighting progress in its registrational-intent Phase 2b trial of ACR-368 in endometrial cancer, including a 52% confirmed overall response rate in sero...
Business Operations and Strategy
Acrivon Highlights Promising ACR-368 Phase 2b Endometrial Data
Positive
Feb 27, 2026
On February 27, 2026, Acrivon Therapeutics hosted a live, company-sponsored key opinion leader panel during the ESGO Congress in Copenhagen to discuss interim Phase 2b data from its registrational-intent ACR-368 trial in endometrial cancer. Expert...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.